The Prime Minister and the Health Secretary announced the Government’s COVID-19 plan for the Autumn and Winter months. The Government still sees vaccines as the UK’s best defence to avoid any further lockdowns and I was interested to note in the press release that ‘building this defence’ will involve pharmaceutical interventions, which I’m sure will include further work in antibody therapies and antivirals.
Dr Jen Vanderhoven, Director of Teesside University’s National Horizons Centre talks about the work being done to establish the UK’s training provision for vaccine manufacturing, advanced therapies and bioprocessing.
As many of you will have spotted on the news, Boris Johnson held a major reshuffle last week. While the headlines have mainly focused on the departure of Dominic Raab and Gavin Williamson, there are also some important changes for life sciences.
We were kindly hosted by Anthony Browne MP in the Terrace Pavilion of the House of Commons for a lunchtime reception where we launched our report ‘Becoming a life sciences superpower’ which includes our recommendations for the Comprehensive Spending Review (CSR) which has been confirmed by the Chancellor to be on the 27 October.
I’m really looking forward to welcoming many of you this Friday to our sector’s premier social event of 2021, the BIA Summer Party at Middle Temple Gardens in London. It’s set to be a great evening of networking and sector celebration with over 400 people coming, if you don’t have a ticket and want to join us, please follow this link.
The BIA together with the Wellcome Sanger Institute and the Medicines Discovery Catapult has launched a new report Genomics Nation, showcasing the strength, breadth and opportunity in the UK’s genomics sector.
The UK’s strength in genomics became evident during the pandemic, where we led the world in the early detection and monitoring of variants of SARS-CoV-2 thanks to a strong genomic infrastructure, a highly skilled workforce and an exceptional collaborative spirit. However, the applications of genomics extend far beyond COVID-19 and are leading the way for a healthier and more sustainable world
Biotech start-ups need substantial sums of money to fund their research and development activities. To attract investors and scale up their operations, founders must put some fundamental building blocks in place and avoid some common pitfalls.
The last week of Parliament before a summer recess often sees a raft of government announcements, as Ministers rush to get things into the public domain before heading off on holiday. Last week was a busy one with several key announcements affecting our sector, including updates on the National Security and Investment Act, the Innovative Medicines Fund, a new BEIS Innovation Strategy and a command paper on Northern Ireland. This was topped off for me by the misleading front page headline on Sunday suggesting “animal testing could end” due to a government review.